Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PCSA Catalyst Timeline
Dated clinical, regulatory and corporate events for Processa Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Processa Pharmaceuticals, Inc.
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How PCSA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-03-31 | PCS6422+Cap (NGC-Cap) | Phase 2 data readout | Phase 2 |
Drug Pipeline Intelligence
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VT7208 Small MoleculesNCT07085507 | Multiple Sclerosis | Phase 1/2 | RECRUITING | 100 | Dec 31, 2027 | ||||||
| RX-3117 Small MoleculesCompletedNCT03189914 | Metastatic Pancreatic Cancer | Phase 1/2 | COMPLETED | 46 | Nov 21, 2019 | ||||||
| RX-3117 Small MoleculesCompletedNCT02030067 | Solid Tumor | Phase 1/2 | COMPLETED | 127 | Dec 1, 2019 | ||||||
| PCS6422 Small MoleculesCompletedNCT04861987 | Advanced Cancer | Phase 1 | COMPLETED | 23 | Sep 9, 2024 | ||||||
| PCS12852 Small MoleculesCompletedNCT05270460 | Gastroparesis | Phase 2 | COMPLETED | 25 | Oct 6, 2022 | ||||||
| PCS499 Small MoleculesCompletedNCT03698864 | Necrobiosis Lipoidica | Phase 2 | COMPLETED | 12 | Feb 25, 2020 |
Clinical Trial Results
Readouts, endpoints and source filings for every PCSA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| NGC-Cap | advanced or metastatic breast cancer | Phase 2 | 2026-01-13 | increases exposure to capecitabine’s cancer-killing metabolites; maintaining a safety profile comparable to standard capecitabine monotherapyRead More | Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare ConferenceRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Ng George KDirector, Officer (Chief Executive Officer) | Option | 1,600 17,092 held | $0.00 | 08/08/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PCSA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 0 % | 263.95 K | 160.94 K |
Ownership Trends
PCSA Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How PCSA ranks across every disease it competes in
PCSA News
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
Processa Pharmaceuticals announced that Executive Chair Sheila Gujrathi will speak at the UBS Global Healthcare Conference and the Evercore ISI HealthCONx Conference. The company also noted that management will host one-on-one investor meetings during these events. These conferences follow the July 2026 acquisition of Vidya Therapeutics for approximately $200 million. Processa now focuses on its lead program VT-7208 for immune-mediated diseases.
Read more →Processa Pharmaceuticals Announces Key Leadership Appointments
Processa Pharmaceuticals announced key leadership appointments to support its growth. Gregory J. Flesher becomes COO, while Craig Coburn, Ashley Hall, and Michael P. Cruse take on executive roles. The company is advancing VT-7208, a Bruton’s tyrosine kinase inhibitor, with FDA clearance for its Phase 2 study in chronic spontaneous urticaria.
Read more →Processa Pharmaceuticals Announces Corporate and Pipeline Progress Following Acquisition of Vidya Therapeutics
Processa Pharmaceuticals announced significant progress following its acquisition of Vidya Therapeutics. The FDA has cleared the IND for a Phase 2 study of VT-7208 in chronic spontaneous urticaria, with additional studies planned. The company also expanded its pipeline through a collaboration with Generian Pharmaceuticals and appointed Dr. Sheila Gujrathi as Executive Chair.
Read more →PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREAS
Processa Pharmaceuticals has announced the acquisition of Vidya Therapeutics, which includes the promising BTK inhibitor VT-7208. This acquisition is complemented by a $200 million private placement financing aimed at advancing VT-7208 through key clinical milestones in food allergy, chronic spontaneous urticaria, and relapsing multiple sclerosis. The funding is expected to sustain operations until the second half of 2029.
Read more →Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference
Processa Pharmaceuticals will attend the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026. CEO George Ng and Chief Business Officer Patrick Lin will hold one-on-one meetings to discuss their clinical pipeline, particularly the Phase 2 study of NGC-Cap for advanced breast cancer. Preliminary data indicate that NGC-Cap enhances exposure to effective metabolites while maintaining safety.
Read more →Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study
Processa Pharmaceuticals has completed the enrollment of 20 patients for a formal interim analysis in its Phase 2 study of NGC-Cap, a combination treatment for advanced breast cancer. This analysis aims to compare the safety and efficacy of NGC-Cap against standard capecitabine therapy. Results are anticipated in the first quarter of 2026, which will guide future study design and dose optimization.
Read more →Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer
Processa Pharmaceuticals provided an update on its Phase 2 study of NGC-Cap, a combination of PCS6422 and capecitabine for metastatic breast cancer. Preliminary data from 16 of 19 patients indicate that NGC-Cap enhances exposure to effective cancer-killing metabolites while maintaining a comparable safety profile to standard capecitabine therapy. The full interim analysis is expected in early 2026.
Read more →Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025
Processa Pharmaceuticals announced that its abstract for the adaptive Phase 2/3 study of PCS499 in patients with FSGS has been accepted for presentation at ASN Kidney Week 2025. The study aims to optimize dosing and address the urgent need for effective therapies in this rare kidney disease. PCS499 has demonstrated a favorable safety profile, potentially allowing for greater therapeutic benefits compared to existing treatments.
Read more →Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies
Processa Pharmaceuticals has announced a strategic investment and is exploring cryptocurrency treasury strategies to enhance financial flexibility and support its clinical development programs. The company aims to diversify its capital base while maintaining compliance with regulatory standards. CEO George Ng emphasized the commitment to delivering meaningful therapies for cancer patients and optimizing outcomes for shareholders.
Read more →Processa Pharmaceuticals Provides Portfolio and Business Update
Processa Pharmaceuticals secured a binding term sheet with Intact Therapeutics for an exclusive option to license PCS12852. The deal offers up to $454 million in milestone payments and a 12% royalty on future sales. The company also raised $7 million through a capital infusion to strengthen its balance sheet. Processa continues enrolling patients in its Phase 2 study of PCS6422 for metastatic breast cancer.
Read more →Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering
Processa Pharmaceuticals announced the pricing of a public offering of 28 million shares at $0.25 each, aiming to raise $7 million. The proceeds will be used to continue the Phase 2 clinical trial for NCG-Cap and for general corporate purposes. The offering is expected to close around June 18, 2025.
Read more →Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate
Processa Pharmaceuticals has signed a binding term sheet with Intact Therapeutics, granting them the exclusive option to license PCS12852, a promising treatment for gastroparesis. The agreement includes a $2.5 million option fee and potential milestone payments exceeding $452 million. PCS12852 has shown strong safety and efficacy in clinical trials, positioning it as a leading candidate for gastrointestinal motility disorders.
Read more →Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025
Processa Pharmaceuticals will participate in the 2025 BIO International Convention in Boston, where its leadership will meet with potential partners and investors. The focus will be on the company's Next Generation Cancer therapies, particularly NGC-Cap, which is currently in a Phase 2 trial for metastatic breast cancer. This event provides an opportunity to showcase their clinical advancements and regulatory science approach.
Read more →Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting
Processa Pharmaceuticals announced that three abstracts regarding its cancer drug pipeline were accepted for the 2025 ASCO Annual Meeting. The presentations cover preclinical data for PCS11T and clinical results for PCS6422 in breast cancer. The company highlighted a Phase 1b study that defined the maximum tolerated dose and recommended phase 2 dose range for the combination therapy. These updates reflect ongoing progress in its next generation cancer programs.
Read more →Processa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025
Processa Pharmaceuticals announced that Dr. David Young will present at the World Orphan Drug Congress USA 2025. His presentation will focus on applying FDA's Project Optimus principles to enhance drug efficacy and safety for rare diseases. This aligns with Processa's mission to develop next-generation cancer therapies.
Read more →Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
Processa Pharmaceuticals will present at the MedInvest Biotech and Pharma Investor Conference on March 28, 2025. The company aims to showcase its innovative cancer therapies that enhance efficacy and safety. Management will also engage in one-on-one meetings with investors during the event. The presentation will be accessible on the company's website.
Read more →Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference
Processa Pharmaceuticals will present at the 2025 BIO CEO & Investor Conference on February 11, 2025. The company aims to showcase its innovative approach to developing next-generation cancer therapies that enhance safety and efficacy. Management will also hold one-on-one meetings with investors during the event, promoting further engagement and collaboration.
Read more →Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
Processa Pharmaceuticals has successfully closed a $5 million public offering priced at-the-market under Nasdaq rules. The offering included participation from the company's CEO, board members, and institutional investors. Gross proceeds are aimed at advancing their pipeline of next-generation chemotherapeutic drugs. The registration statement for the offering was declared effective by the SEC shortly before the closing date.
Read more →Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
Processa Pharmaceuticals has announced the pricing of a $5 million public offering, which includes 8,050,672 shares of common stock and accompanying Series A and B warrants. The offering is led by the company's CEO and various board members, with institutional investor involvement. The completion of the offering is subject to customary closing conditions and is expected to close by January 29, 2025. Additionally, the company will seek stockholder approval for the issuance of shares related to the warrants within 90 days post-offering.
Read more →